Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Quarterly results
Director comp.
Director departure
Appointed director
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "NeuroOne Medical Technologies Corporation Condensed Balance Sheets June 30, 2023 September 30, 2022 Assets Current assets: Cash and cash equivalents $ 3,083,458 $ 8,160,329 Short-term investments — 2,981,010 Accounts receivable — 33,237 Inventory 1,516,527 704,538 Prepaids and other 278,786 296,649 Total current assets 4,878,771 12,175,763 Intangible assets, net 95,156 111,892 Right-of-use asset 197,324 181,355 Property and equipment, net 586,873 353,599 Total assets $ 5,758,124 $ 12,822,609 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 958,811 $ 927,662 Accrued expenses and other liabilities 789,097 715,839 Deferred revenue — 1,455,188 Total current liabilities 1,747,908 3,098,689 Operating lease liability, long term 88,918 119,556 Total liabilities 1,836,82..."
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/01/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
07/27/2023 8-K Asset disposition
Docs: "5,250,000 Shares 1 NEUROONE MEDICAL TECHNOLOGIES CORPORATION Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT",
"OPINION OF HONIGMAN LLP",
"NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock",
"NeuroOne Medical Technologies Corporation Announces Pricing of Public Offering of Common Stock"
07/26/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/24/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/24/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/12/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "NeuroOne Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update EDEN PRAIRIE, Minn., May 11, 2023 -- NeuroOne Medical Technologies Corporation , a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the fiscal second quarter 2023 ended March 31, 2023. Fiscal Second Quarter 2023 and Recent Business Updates Evo sEEG: ● Announced the commercial launch of the Evo sEEG electrode product line in the United States with exclusive distribution partner Zimmer Biomet. The new technology potentially provides NeuroOne with a new revenue stream. ● The first clinical case using the Evo sEEG electrode was performed at the Mayo Clinic usin..."
03/17/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
02/22/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/13/2023 10-Q Quarterly Report for the period ended December 31, 2022
01/27/2023 ARS Form ARS - Annual Report to Security Holders:
01/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
01/13/2023 8-K Other Events  Interactive Data
12/22/2022 8-K Quarterly results
12/22/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
12/21/2022 10-K Annual Report for the period ended September 30, 2022
12/16/2022 8-K Quarterly results
10/25/2022 8-K Quarterly results
09/14/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "CORPORATE FACT SHEET, DATED SEPTEMBER 2022"
08/11/2022 8-K Quarterly results
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/03/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "WARRANT TO PURCHASE COMMON STOCK",
"THIRD AMENDMENT TO EXCLUSIVE DISTRIBUTION AND DEVELOPMENT AGREEMENT",
"NeuroOne Announces $3.5 Million Accelerated Milestone Payment from Zimmer Biomet for Evo ® sEEG Electrode"
06/02/2022 8-K Quarterly results
05/31/2022 10-K/A Annual Report for the period ended September 30, 2021 [amend]
05/16/2022 8-K Quarterly results
05/12/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/12/2022 8-K Quarterly results
04/29/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/25/2022 8-K Other Events  Interactive Data
02/14/2022 8-K Quarterly results
Docs: "NeuroOne Reports First Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update EDEN PRAIRIE, Minn., February 14, 2022 -- NeuroOne Medical Technologies Corporation , a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders today announces its operating results for the first quarter of fiscal year 2022 ended December 31, 2021. First Quarter and Recent Business Updates"
02/14/2022 10-Q Quarterly Report for the period ended December 31, 2021
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy